The role of the histone H3 variant CENPA in prostate cancer.
Anjan K SahaRafael Contreras-GalindoYashar S NiknafsMatthew IyerTingting QinKarthik PadmanabhanJaved SiddiquiMonica PalandeClaire WangBrian QianElizabeth WardTara TangScott A TomlinsScott D GitlinMaureen A SartorGilbert S OmennArul M ChinnaiyanDavid M MarkovitzPublished in: The Journal of biological chemistry (2020)
Overexpression of centromeric proteins has been identified in a number of human malignancies, but the functional and mechanistic contributions of these proteins to disease progression have not been characterized. The centromeric histone H3 variant centromere protein A (CENPA) is an epigenetic mark that determines centromere identity. Here, using an array of approaches, including RNA-sequencing and ChIP-sequencing analyses, immunohistochemistry-based tissue microarrays, and various cell biology assays, we demonstrate that CENPA is highly overexpressed in prostate cancer in both tissue and cell lines and that the level of CENPA expression correlates with the disease stage in a large cohort of patients. Gain-of-function and loss-of-function experiments confirmed that CENPA promotes prostate cancer cell line growth. The results from the integrated sequencing experiments suggested a previously unidentified function of CENPA as a transcriptional regulator that modulates expression of critical proliferation, cell-cycle, and centromere/kinetochore genes. Taken together, our findings show that CENPA overexpression is crucial to prostate cancer growth.
Keyphrases
- prostate cancer
- cell cycle
- radical prostatectomy
- single cell
- cell proliferation
- high throughput
- poor prognosis
- transcription factor
- end stage renal disease
- endothelial cells
- binding protein
- ejection fraction
- newly diagnosed
- chronic kidney disease
- genome wide
- prognostic factors
- stem cells
- circulating tumor cells
- signaling pathway
- long non coding rna
- high density